NLRP3 and colitis: Based on the findings from in vitro experiments indicating that ruscogenin exhibited the ability to inhibit inflammation and pyroptosis, we proceeded to explore whether ruscogenin could alleviate DSS-induced colitis by inhibiting the NLRP3 inflammasome and pyroptosis via the TLR4–NF-κB signaling pathway.